Biopharma M&A Accelerates in H1 2026: Eli Lilly Leads with Over $25 Billion Spend as Big Pharma Bolsters Pipelines

July 5, 2026

BioPharma Dive USA

Overview

Biopharmaceutical M&A activity significantly accelerated in the first half of 2026, with over 50 deals transacted. Eli Lilly was notably active, spending over $25 billion and solidifying its position as a major acquirer. This strategic drive reflects big pharma’s efforts to acquire innovative technologies and late-stage pipelines to strengthen portfolios amidst patent expirations and revenue pressures. Acquisitions were particularly vibrant in oncology, rare diseases, immunology, and cell and gene therapy.

In Depth

Key Findings

The first half of 2026 witnessed a substantial acceleration in biopharmaceutical mergers and acquisitions (M&A) activity, with over 50 deals being completed. Eli Lilly emerged as a dominant force, investing more than $25 billion across several strategic acquisitions, positioning itself as one of the most aggressive buyers in the industry. This resurgence signals a strong recovery in the M&A market following a relatively quiet period in 2021 and 2022.

Technical / Clinical Details

The M&A surge is largely driven by large pharmaceutical companies strategically aiming to bridge pipeline gaps and secure future growth. A strong emphasis is placed on acquiring access to novel drugs, groundbreaking platform technologies, and late-stage clinical candidates. Merck KGaA pursued acquisitions to enhance its Life Science division, while AbbVie acquired Apogee Therapeutics to deepen its next-generation immunology pipeline. Notable transactions also include GSK’s acquisition of Nuvalent for $10.6 billion. These deals indicate an expanding scope of strategic M&A beyond therapeutic pipelines to include infrastructure enabling biopharmaceutical R&D and manufacturing, highlighting the importance of technology acquisition and manufacturing capacity.

Background & Context

Major pharmaceutical companies are confronting challenges such as patent cliffs for existing products and increasing revenue pressures, prompting them to acquire innovative biotechnology firms to overcome these hurdles. While oncology remains a central focus for M&A, there is a growing interest in high-growth, high-value areas like immunology, neuroscience, rare diseases, metabolic disorders, radiopharmaceuticals, and cell and gene therapies. Venture capital funding also continues to flow robustly into the sector, with companies like Lycia Therapeutics raising $75 million in Series D funding and Oblenio securing $62 million, indicating a strong capital influx supporting innovation across the biopharmaceutical industry. This M&A revival suggests the industry is entering a new growth cycle.

Strategic Significance & Outlook

This accelerating trend in biopharma M&A is expected to continue, with large pharmaceutical companies actively pursuing investments in younger biotechnology firms possessing innovative therapies or platform technologies, especially in areas with high unmet medical needs such as rare diseases, oncology, and autoimmune conditions. This will likely reshape the competitive landscape of the pharmaceutical industry and accelerate the introduction of new treatments to the market. For investors and researchers, tracking M&A activities will be crucial for identifying future technology trends and promising companies that are poised for significant impact.

Source: https://www.biopharmadive.com/news/biotech-ma-accelerating-tracker-2026/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.